Provectus: Strong Sell, Ties To Paid Stock Promoters, SEC Halt Risk, Price Target $0

About: Provectus Biopharmaceuticals, Inc. (PVCT), Includes: CANN, CBGI, FSPM, GNBT, MYL, ONBI, PHOT, PTOG, RGIN
by: The Pump Stopper
This article is exclusive for subscribers.
The Pump Stopper
Long/short equity, short only, special situations, contrarian

PVCT has just FOUR full-time employees, HQ appears to be a metal barn in rural Knoxville, claim to have effective treatment for cancer with commodity red dye "Rose Bengal."

PVCT is connected to questionable paid stock promoters whose other recommendations have recently been halted by the SEC: including FSPM, PHOT, and PTOG.

Insiders were paid ~$49m during a 12+ year period while PVCT shareholders accumulated losses ~$150m with zero revenue and shares outstanding have increased 20x.

PV-10 has no Phase 3 trial in sight while patents begin expiring in 2016 and appears to have failed their FDA Breakthrough Designation Request.

PVCT appears extraordinarily overvalued with ~$750 MILLION fully diluted valuation. I believe fair value is closer to $0 and outline why in this report.

  • Summary

I believe shares of Provectus Pharmaceuticals (OTC:PVCT) are worthless. This report outlines connections between PVCT and some of Wall Street's shadiest participants. The report further outlines a consistent pattern of substantial shareholder